ZURICH, Switzerland, November 4, 2011 /PRNewswire/ --
Major milestone achieved in the commercial launch of new technology in the treatment of patients with refractory ascites due to liver cirrhosis.
Sequana Medical, the Medical University of Vienna and Vienna General Hospital (AKH Wien) reported that the first two commercial implants worldwide of the ALFApump System were performed at Vienna General Hospital in October, under the supervision of Univ. Prof. Dr. Markus Peck-Radosavljevic, Vice-Chairman, Division of Gastroenterology and Hepatology (Chairman: Prof. Dr. M. Trauner), Dept. of Internal Medicine III. Vienna General Hospital is one of Europe's largest teaching hospitals. The ALFApump System is indicated for the management of refractory and recurrent ascites due to liver cirrhosis, a condition where massive and uncontrolled fluid accumulation occurs in the abdominal cavity.
"I believe that the ALFApump System represents a real breakthrough in the treatment of refractory ascites. By using the ALFApump, the patient no longer has to return to the hospital on a frequent basis to undergo drainage procedures. This positively impacts on both Quality of Life of the patient and the financial burden to the healthcare system. The implant procedure for both patients went smoothly and without complications", commented Professor Peck-Radosavljevic.
Refractory ascites occurs when patients with ascites no longer respond to medical therapy. This condition affects over 100,000 patients in Europe and the US every year. The number of patients suffering from ascites is growing at approximately 10% a year due to the accelerating incidence of hepatitis- and obesity-related liver disease. The primary treatment for ascites is paracentesis, a procedure in which a large bore needle is inserted into the patient's abdomen to remove between 5-10 litres of ascites that has accumulated over a period of a week or two. The cumulative cost of ascites-related
|SOURCE Sequana Medical AG|
Copyright©2010 PR Newswire.
All rights reserved